Dr. Jai Shankar, MD FRCPC
Claim this profileHealth Sciences Centre
Studies Stroke
Studies Oral Mucosa Hematoma
6 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Jai Shankar, MD FRCPC is currently running
DECT
for Stroke
The goal of this clinical trial is to investigate the use of DECT (Dual-Energy Computed Tomography) in patients with acute ischemic stroke who receive an intervention (thrombolysis or thrombectomy). The main questions to answer are: 1. Can DECT more accurately differentiate hyperdensities as intracranial haemorrhage (ICH) or contrast extravasation compared with single-energy CT (SECT)?. 2. Will DECT lead to better care for patients with AIS who receive intervention and have post-procedural hyperdensities? Patients who receive intervention for acute ischemic stroke (AIS) receive a SECT at 24 hours as standard of care to determine if ICH is present. In the current study, a DECT will be done in addition to the SECT. Followup imaging (SECT or MRI) will be done at 72 hours to determine if the hyperdensity was indeed ICH. The accuracy of DECT for differentiating ICH from contrast extravasation will be compared.
Recruiting1 award N/A1 criteria
Middle Meningeal Artery Embolization
for Subdural Hematoma
This trial is testing whether an additional procedure can help prevent brain bleeds in patients who have already received usual care. The goal is to see if this extra step can reduce the risk of the brain bleed coming back.
Recruiting1 award N/A3 criteria
More about Jai Shankar, MD FRCPC
Clinical Trial Related4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jai Shankar, MD FRCPC has experience with
- Immediate Mechanical Thrombectomy(iMT) Using EmboTrap II Revascularization Device
- Immediate Mechanical Thrombectomy(iMT) Using EmboTrap Revascularization Device
- Initial Medical Management (iMM)
- EMMA
- CT Perfusion
- Embolization Of The Middle Meningeal Artery
Breakdown of trials Jai Shankar, MD FRCPC has run
Oral Mucosa Hematoma
Hematoma
Subdural Hematoma
Ischemic Encephalopathy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jai Shankar, MD FRCPC specialize in?
Jai Shankar, MD FRCPC focuses on Stroke and Oral Mucosa Hematoma. In particular, much of their work with Stroke has involved treating patients, or patients who are undergoing treatment.
Is Jai Shankar, MD FRCPC currently recruiting for clinical trials?
Yes, Jai Shankar, MD FRCPC is currently recruiting for 3 clinical trials in Winnipeg Manitoba. If you're interested in participating, you should apply.
Are there any treatments that Jai Shankar, MD FRCPC has studied deeply?
Yes, Jai Shankar, MD FRCPC has studied treatments such as Immediate mechanical thrombectomy(iMT) using EmboTrap II Revascularization Device, Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device, Initial medical management (iMM).
What is the best way to schedule an appointment with Jai Shankar, MD FRCPC?
Apply for one of the trials that Jai Shankar, MD FRCPC is conducting.
What is the office address of Jai Shankar, MD FRCPC?
The office of Jai Shankar, MD FRCPC is located at: Health Sciences Centre, Winnipeg, Manitoba R3A 1R9 Canada. This is the address for their practice at the Health Sciences Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.